Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994. However, it was recently approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs. It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.
Related Prodcuts:
Doramectin; Spinosad; Moxidectin; Milbemycin oxime; Imidacloprid; Fumagillin; Trilostane; Pimobendan; Maropitant Citrate; Fluralaner; Afoxolaner; Tiamulin famarate; Selamectin